Vimarsana
Biggest News Aggregation in the World

Page 2 - Scientific Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Presentations Today - Breaking & Trending Today

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference - Vimarsana News

4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference

Initial interim landmark data analysis to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET ...

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress - Vimarsana News

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

30.10.2023 - Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is currently in Phase 1 Clinical Development Tonix is Developing TNX-1500 for Prevention of Kidney Allograft Rejection as the First ... Seite 1

'Grow, Connect, and Be Inspired' at CHEST 2023 - Vimarsana News

'Grow, Connect, and Be Inspired' at CHEST 2023

The annual meeting will feature the latest in pulmonary, critical care, and sleep medicine, plus acrobatic fire dancers and a luau feast.

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023 - Vimarsana News

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023

MTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700 shows single agent activity and additive effects in combination with anti-PD-1 mTNX-1700 targets myeloid-derived suppressor cells (MDSCs) in a novel mechanism to treat cancer CHATHAM, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today

Source: yahoo.com
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at - Vimarsana News

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE...